Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)

Neuropsychobiology

Volumn 56, Issue 2-3, 2008, Pages 73-85

  Mallinckrodt, Craig H ^a   Prakash, Apurva ^a   Houston, John P ^a   Swindle, Ralph ^a   Detke, Michael J ^a,b,c,d   Fava, Maurizio ^d  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCLEAN HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressant; Duloxetine; Major depressive disorder, symptom severity; Selective serotonin reuptake inhibitor

Indexed keywords

DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; HAMILTON SCALE; HUMAN; HYPOCHONDRIASIS; INSOMNIA; MAJOR DEPRESSION; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; SOMATIZATION; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME; WORK CAPACITY;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; THIOPHENES; TREATMENT OUTCOME;

EID: 40349111453     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111537     Document Type: Article

References (43)

1. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M: Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001;286:2947-2955.
2. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS: Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-426.
3. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC: Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of fewer agents. Biol Psychiatry, in press.
4. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
5. Stahl SM, Entsuah R, Rudolph RL: Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-1174.
6. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(4 suppl):1-45.
7. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61.
8. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
9. Gibbons RD, Clark DC, Kupfer DJ: Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993;27:259-273.
10. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ: The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000;34:3-10.
11. Entsuah R, Shaffer M, Zhang J: A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. J Psychiatr Res 2002;36:437-448.
12. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231.
13. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-132.
14. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399.
15. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-470.
16. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ: Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006;21:367-378.
17. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Current Medical Research and Opinion 2007;23:401-416.
18. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB: Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005;30:445-460.
19. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315.
20. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390.
21. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909.
22. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF: Duloxetine 60 mg once daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53.
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
24. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138.
25. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
26. Maier W, Philipp M: Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-115.
27. Cleary P, Guy W: Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res 1977;1:115-120.
28. Zohar J, Keegstra H, Barrelet L: Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol 2003;18:113-119.
29. Tignol J, Stoker MJ, Dunbar GC: Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992;7:91-94.
30. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S: Hamilton Depression Rating Scale: extracted from regular and change versions of the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1981;38:98-103.
31. Ruhe HG, Dekker JJ, Peen J, Homan R, de Jonghe F: Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry 2005;46:417-427.
32. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, Woo A, Trivedi MH: The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006;16:601-611.
33. Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM: Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337-348.
34. Khan A, Detke M, Khan SR, Mallinckrodt C: Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003;191:211-218.
35. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404.
36. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A: Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004;29:566-579.
37. Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M: Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res 2007;149:195-200.
38. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ: Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-692.
39. Clayton AH, Kornstein SG, Prakash A, Mallinckrodt CH, Wohlreich MM: Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4:917-929.
40. Katon W, Kleinman A, Rosen G: Depression and somatization: a review. Part I. Am J Med 1982;72:127-135.
41. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28.
42. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880.
43. Fava M, Rush AJ: Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139-153.